Liraglutide Safely Lowers Cardiovascular Risk By 13 Percent In Patients With Type 2 Diabetes After almost four years of clinical trials, a study on liraglutide has finally concluded. Results showed that the injectable drug can reduce cardiovascular risk by 13 percent in patients with type 2 diabetes, without any serious adverse effects. by Catherine Cabral-Isabedra